Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00343499
Status:
TERMINATED
Last Update Posted:
2008-08-21
First Post:
2006-06-21
Brief Title:
The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial the DRAFT Trial
Sponsor:
Intermountain Health Care Inc
Organization:
Intermountain Health Care Inc
Study Overview
Official Title:
A Single Center Randomized Trial to Evaluate the Effects of Diovan to Maintain Sinus Rhythm in Patients With Persistent Atrial Fibrillation
Status:
TERMINATED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Inability to recruit
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
24 week single center prospective randomized double-blind treatment study of valsartan 80 mgbid increased to 160 mgbid or placebo in addition to other general medical therapy in patients with persistent atrial fibrillation AF undergoing electrical cardioversion to restore normal sinus rhythm SR
Detailed Description:
To evaluate the efficacy of valsartan added to standard AF therapy to maintain sinus rhythm and extend the interval to first AF recurrence after cardioversionEvaluate the efficacy of valsartan begun prior to cardioversion on the difficulty number and total energy of CV attempts the net rate of cardioversion to SR for 10 minutes and early AF recurrence rate within 24 hours
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None